Preliminary study on the formulation of syariah 

compliant generic sustained release gliclazide tablet 

using xanthan gum by Mat Zin, Nik Mohamad Lukman et al.
IMJM Volume 17 Special Issue No 2 
2nd World Congress on Integration and Islamicisation  
1 
Preliminary Study on the Formulation of Syariah 
Compliant Generic Sustained Release Gliclazide Tablet 
Using Xanthan Gum 
Nik Mohamad Lukman Mat Zin1, Anis Syazwani Abd Mubin1, Mohamed Sufian Mohd Nawi1, Abul Bashar 
Mohammed Helaluddin1, Abdul Razak Kasmuri1, Uttam Kumar Mandal2 
1Kuliyyah of Pharmacy, International Islamic University Malaysia Kuantan. 
2Department of Pharmacy, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Bathinda,India 
ABSTRACT 
 
Gliclazide (1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea) is a 
second-generation sulfonylurea which is orally administered in the treatment of non-insulin-dependent 
diabetes mellitus in adults. Sustain release drugs help to improve drugs bioavailability by controlling the 
time of drug release or prolonging it. We are reporting the preliminary formulation of sustain release 
gliclazide tablets with careful choice of all the ingredients and processes related to syariah compliance 
manufacturing of pharmaceutical products. In this work, xanthan gum, a natural gum was used to achieve 
the sustain release criteria. The tablets were produced by wet granulation and semi-automatic tableting 
process. Tablet characterisation was done following the British Pharmacopoeia (BP) criteria. We expect that 
the outcome of our study will result in a suitable formulation that could be useful for the formulation of 
such product that will be helpful for the Muslim patient especially during the fasting month. 
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INTRODUCTION 
 
Gliclazide(1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta 
[c]pyrrol-2-yl)-3-(4-methylphenyl) sulfony urea) is 
widely used as antidiabetic. It is a second-generation 
sulfonylurea which is orally administered in the 
treatment of non-insulin-dependent diabetes 
mellitus in adults when dietary measures, physical 
exercise and weight loss alone are not sufficient to 
control blood glucose. It  has a duration of action of 
12 hours or more. It is readily absorbed from the 
gastro-intestinal tract and extensively metabolized 
in the liver by hydroxylation, N-oxidation and 
oxidation to a number of inactive metabolites. 
Approximately 60-70% of a dose is excreted in the 
urine with less than 5% as unchanged drug. 
Approximately 10-20% of the dose is eliminated in 
the faeces as metabolites. It is protein human 
plasma bound with plasma half-life of 6-14 hours.1  
 
Sulfonylureas were believed to be unsuitable for use 
during fasting because of the inherent risk of 
hypoglycemia. Use of chlorpropamide is absolutely 
contraindicated during fasting because of the high 
possibility of prolonged and unpredictable 
hypoglycemia. However, a newer member of the 
sulfonylurea family such as gliclazide modified 
release has been shown to be effective, resulting in 
a lower risk of hypoglycaemia.2   
 
Gliclazide is less soluble in water but it is well 
absorbed from the gastro-intestinal tract. The 
remaining of gliclazide in gastro-intestinal tract 
should be prolonged by applying it in controlled 
release form. Several formulations were applied to 
fulfil this criteria such as floating tablets of 
gliclazide using HPMC K100M, HPMC K4M and 
carbopol 934P,3(microencapsulation using natural 
polymers.4 and sustained release gliclazide by wet 
granulation using hydroxy propyl methyl cellulose, 
hydroxy propyl cellulose and their combination as 
polymers.5 The brand medicines for gliclazide 
modified release ready in the market are 
Diamicron® 60 mg MR and Diamicron® 30 mg MR by 
Servier Laboratories Limited, Ireland. 
 
Syariah compliance in pharmaceuticals requires all 
manufacturing raw materials be free from 
prohibited (non-Halal) sources. Besides, processes 
related to syariah compliance manufacturing of 
pharmaceutical products should also be 
implemented.6  The aim of this study is to formulate 
a syariah compliance gliclazide tablet that is 
suitable to work in stages and also to develop 
analytical method for quantitative analysis of 
gliclazide tablet produced. In formulation stage, 
xanthan gum was used to control the drug release 
because it is a “halal” natural polymer. An HPLC 
method was used to detect the presence of 
gliclazide in the dosage form. In this paper, we are 
reporting the preliminary findings of the physical 
characteristics of the tablet that has been produced 
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in our laboratory. 
 
Instrument 
 
Throughout the experiment, an oven (Memmert UM400, 
Germany), a moisture balance (Mettler Toledo 
HR83-P, Switzerland), a 4 mm test sieve (Retsch, 
Germany), a 1 mm test sieve (Fisher Scientific 
Company, USA), a rotary tablet press machine 
(Rimek Mini Press 2, India), a micropipette 
(Eppendorf Research, Germany), an analytical 
balance (Mettler Toledo AX205 Delta Range, 
Switzerland), a manual tablet testing machine 
(Pharmatest PTB 311E, Germany), an electronic 
balance (Ohaus Adventurer AR3130, USA), a friability 
tester machine (SOTAX Friability Tester F2 CH-4123, 
Switzerland), Whatman® 0.45 µm membrane filters 
and an Agilent 1100 Series HPLC System (USA) were 
used. 
 
Besides, glasswares of suitable grade were also used 
throughout the production and the quality assessment 
of the tablets. 
  
MATERIALS  
 
Industrial grade gliclazide, xantham gum, lactose, 
polyvinylpyrrolidone K30  (PVP K30), magnesium stearate 
and talcum were purchased from IKOP Sdn. Bhd., 
Kulliyyah of Pharmacy, International Islamic 
University of Malaysia, which fulfilled  the 
requirement for syariah compliance. 
 
For HPLC, acetonitrile (ACN) of isocratic HPLC grade 
was purchased from Scharlab, Spain while 
triethylamine (TEA) and phosphoric acid, both of 
HPLC grade were purchased from Fisher Scientific, 
United Kingdom. The ultra-pure (UP) water used 
was obtained from the water purification system 
(Human Coproration NEX Power 4000, South Korea). 
 
METHODS 
Preparation of tablets 
 
Fifteen grams of gliclazide, 12.5 g of xanthan gum 
and 45.0 g of lactose were thoroughly mixed using 
mortar and pestle by following the trituration 
method. The binding solution was prepared by 
dissolving 2.5 g of PVP K30 in 10 ml distilled water. 
Then, 6 ml of the binding solution was added into 
the powder portion by portion using a micropipette 
(Eppendorf Research, Germany) while thoroughly 
mixed to form a dough. The dough was forced 
through a 4 mm sieve to produce wet granules. The 
wet granules were dried at 50°C for 2 hours in an 
oven (Memmert UM400, Germany). The granules 
were tested for their moisture content using a 
moisture balance (Mettler Toledo HR83-P, Switzerland) 
before and during the drying process and the drying 
process ended when the moisture content was 3%. 
The dried granules were then forced through a 1 
mm sieve to break the aggregates. Magnesium 
stearate and talcum powder (0.5 g each) were 
added and thoroughly mixed to the dry granules as 
the lubricant and glidant respectively. The mixture 
was manually weighted for portions of 300 mg in 
separate weighing boats for the tableting process. 
Finally, the tablet granules were compressed using a 
rotary tablet press machine (Rimek Mini Press 2, 
India). The tablets were stored in a screw capped 
glass bottle. 
 
Weight variation test 
 
Twenty tablets were taken randomly and weighted 
using an analytical balance (Mettler Toledo AX205 
Delta Range, Switzerland). Average mass of the 
tablets was calculated. The percentage of deviation 
of the weight of individual tablet from the average 
weight was calculated using equation 1. The 
deviation of individual weight from the average 
weight should not exceed 5%.7 
 
The formula used to calculate the deviation was: 
 
Deviation (%) = ×100   
 
Equation 1   
 
 
 
Tablet hardness  
 
Hardness test was conducted using a manual tablet 
testing machine (Pharmatest PTB 311E, Germany) . 
The tablets were placed between the jaws of the 
machine. Ten tablets were used for this test and all 
fragments of tablets were removed before each 
determination.8The results were expressed as the 
mean, minimum and maximum values of the force 
measured.9 
 
Friability test 
 
Twenty two tablets were randomly chosen and 
carefully dedusted. All of the tablets were weighted 
using the electronic balance (Ohaus Adventurer 
AR3130, USA) and the data was recorded. All of the 
tablets were loaded into the drum of a friability 
tester machine (SOTAX Friability Tester F2 CH-4123, 
Switzerland). The drum was set to rotate for 100 
times. After being removed from the drum, the 
tablets were carefully dedusted and weighted once 
again to measure weight loss from the test.10 
 
Assay of gliclazide tablet 
 
The presence of the gliclazide in the tablets were 
determined by a high-performance liquid 
chromatography technique (HPLC) adopted from 
British Pharmacopoeia 2015. Gliclazide standard 
solution was prepared by dissolving 40 mg of 
gliclazide in 10 ml acetonitrile (ACN). The solution 
was diluted 20 times with a mixture of 2 volumes of 
ACN and 3 volumes of ultra-pure water. One ml of 
the diluted solution was filtered using Whatman® 
0.45 µm membrane filter before storing into an 
HPLC vial. 
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For the gliclazide tablet sample preparation, 20 
tablets were weighted using an analytical balance  
(Mettler Toledo AX205 Delta Range, Switzerland) 
and crushed into fine powder using mortar and 
pestle. One gram of the tablet powder was shaken 
for an hour with 50 ml ACN in 50 ml Eppendorf 
Tube® and filtered using a Whatman® filter paper 
grade 1. The filtrate was diluted 20 times with a 
mixture of 2 volumes of ACN and 3 volumes of ultra-
pure water. One ml of the diluted sample solution 
was filtered using Whatman® 0.45 µm filter and 
stored in an HPLC vial. The HPLC analysis method 
was carried out using the Agilent 1100 Series HPLC 
System (USA) with a diode array detector (DAD) as 
the detector. The mobile phases used were 
triethylamine (TEA) and ACN in the ratio of 43:57 
respectively. The column used was Agilent Eclipse 
Plus C18 column (USA). The UV wavelength detector 
was set to 229 nm and the flow rate was set to 1.00 
ml per minute.  
 
RESULTS AND DISCUSSION 
Preparation of tablets 
The components of the tablet and their composition 
are listed in Table I. 
Table I: Components of the proposed gliclazide tablet 
Physical properties of tablets 
 
The individual and the average weight of the 20 
tablets are shown in Table II. The average weight of 
a tablet is 303mg with none of the tablet deviating 
more than 5% from the average weight. The 
resistance to crushing (hardness) of the tablets was 
within 62.4 N to 87.2 N with the mean value of 
74.02 N (Table III).  The weight loss from the 
friability test was less than 0.4%. This result 
indicated that the tablets met the specification by 
British Pharmacopoeia 2015.7,9.10  
Name Amount per tablet (mg) 
Gliclazide 60 
PVP K30 6 
Xanthan Gum 50 
Lactose 180 
Magnesium Stearate 2 
Talcum powder 2 
Total 300 
      Table II: Individual weight of 20 tablets. 
Tablet number 1 2 3 4 5 6 7 8 9 10 
Weight (g) 0.301 0.301 0.305 0.300 0.303 0.305 0.306 0.299 0.305 0.301 
Deviation from 
mean (%) 0.66 0.66 0.66 0.99 0 0.66 0.99 1.32 0.66 0.66 
                      
Tablet number 11 12 13 14 15 16 17 18 19 20 
Weight (g) 0.303 0.307 0.300 0.302 0.302 0.301 0.299 0.301 0.304 0.308 
Deviation from 
mean (%) 0 1.32 0 0.33 0.33 0.66 1.32 0.66 0.33 1.62 
Table III: Hardness for 10 tablets. 
 
Tablet number 1 2 3 4 5 6 7 8 9 10 
  
Mean 
 
 
Hardness (N) 72.0 62.4 78.2 74.7 69.7 74.1 71.6 87.2 79.6 70.7 
  
 
74.02 
Assay of gliclazide tablet 
 
Figure 1: HPLC-DAD chromatograms of the gliclazide 
standard, gliclazide sample, blank and placebo.        
 
Figure 1 shows the overlaid chromatograms of the 
gliclazide standard, gliclazide tablet, blank and 
placebo. The figure shows the presence of a peak at 
min=3.917 for both gliclazide standard and gliclazide 
sample. This indicates the presence of gliclazide in 
the tablet. However, the quantitative result is not 
reported here. The method optimisation for 
quantitative analysis of gliclazide in our new 
formulated tablets using HPLC is in progress. 
 
 
CONCLUSION 
Xanthan gum is a potential release-retarding 
material in the formulation of halal sustained 
release gliclazide tablet by wet granulation 
technique. Nevertheless, release profile and 
quantitative content of gliclazide studies of these 
tablets should be conducted before further 
improvement to the tablet formulation could be 
performed.  
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